Xellia Pharmaceuticals signs agreement with ProMark
04 Oct 2018

The agreement covers a standard ProMark solution for 600 employees in Denmark which will be implemented in 2 phases.

Xellia Pharmaceuticals has just signed an agreement on implementation of a standard ProMark solution for 600 employees in Denmark after a fairly comprehensive tendering process.

The solution will be implemented in 2 phases and includes:

Phase 1:

  • Time & Attendance and absence registration for the hourly-paid employees
  • Registration via web portal and terminals
  • Automatic email notifications in case of missing registrations and/or approvals
  • Integration to SAP SuccessFactors and Visma payroll
  • Absence analysis
  • Web-based staff roster planning

Phase 2:

  • Mobile registration via our app with a self-service opportunity

The project will start up at the end of October.

About

Xellia Pharmaceuticals s a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections. Headquartered in Copenhagen, Denmark and owned by Novo Holdings A/S, Xellia Pharmaceuticals has more than 1500 employees globally.

Related content